Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;81(3):226-35.
doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation

Guanghua Chen  1 , Depei Wu, Yi Wang, Jiannong Cen, Yufeng Feng, Aining Sun, Xiaowen Tang, Huirong Chang, Ziling Zhu
Affiliations

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation

Guanghua Chen et al. Eur J Haematol. 2008 Sep.

Abstract

Graft-versus-host disease (GVHD), leukemia relapse, and immune deficiency remain the major limitations of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Donor natural killer cells (NK) and cytokines have good potential in GVHD prevention and immune reconstitution enhancement. Improved survival after allo-HSCT therefore requires effective prophylaxis to reduce GVHD and strategy to mediate graft-versus-leukemia (GVL) effect. We studied the administration of expanded donor NK cell infusion and interleukin-2 (IL-2) and IL-15 mixture treatment in a murine allo-HSCT model for its effects on GVHD, immune reconstitution and leukemia relapse. In the GVHD model, recipient mice were reconstituted with bone marrow (BM) cells and splenocytes via vein. In the leukemia model, recipient mice were inoculated with EL9611 leukemia cells via vein 8 d prior to transplant. NK cell infusion mice group had lower clinical GVHD scores and suffered less severe GVHD-associated weight loss than control mice group. 90% of control mice died of leukemia relapse within 52 d post-transplant. NK cell infusion and IL-2 and IL-15 treatment recipient mice had improved survival compared with control mice. NK cell infusion and IL-2 and IL-15 treatment recipient mice had also accelerated lymphoid immune reconstitution compared with control mice group. Expanded donor NK cell infusion and IL-2 and IL-15 treatment could promote lymphoid immune reconstitution, mitigate GVHD, and reduce leukemia relapse in allo-HSCT recipients. The findings may have important significance for complication prevention in clinical allo-HSCT.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
    Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah … See abstract for full author list ➔ Mathew NR, et al. Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Nat Med. 2018. PMID: 29431743 Free PMC article.
  • Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.
    Capitini CM, Fry TJ, Mackall CL. Capitini CM, et al. Am J Immunol. 2009 Jan 1;5(3):65-83. doi: 10.3844/ajisp.2009.65.83. Am J Immunol. 2009. PMID: 20182648 Free PMC article.
  • Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.
    Kang S, Li Y, Qiao J, Meng X, He Z, Gao X, Yu L. Kang S, et al. Front Oncol. 2022 Mar 9;12:787108. doi: 10.3389/fonc.2022.787108. eCollection 2022. Front Oncol. 2022. PMID: 35356211 Free PMC article. Review.
  • [Progress on allogeneic hematopoietic stem cell transplantation in peripheral T cell lymphoma].
    Yin G, Li J, Miao K. Yin G, et al. Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):343-7. doi: 10.3760/cma.j.issn.0253-2727.2016.04.020. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27094002 Free PMC article. Chinese. No abstract available.
  • Finding potential _targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.
    Kheirkhah AH, Habibi S, Yousefi MH, Mehri S, Ma B, Saleh M, Kavianpour M. Kheirkhah AH, et al. Front Immunol. 2024 Sep 30;15:1460437. doi: 10.3389/fimmu.2024.1460437. eCollection 2024. Front Immunol. 2024. PMID: 39411712 Free PMC article. Review.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

  NODES
admin 3
twitter 2